Cholinergic function and Alzheimer's disease
- PMID: 12973744
- DOI: 10.1002/gps.935
Cholinergic function and Alzheimer's disease
Abstract
Deficits in cholinergic function contribute to the pathology of Alzheimer's disease (AD), affecting cognition, behaviour and activities of daily living. Pharmacological intervention directed towards these deficits is based on acetylcholinesterase (AChE) inhibition. Whether such drugs have reached their therapeutic 'ceiling' is an open question and it is possible that cholinergic intervention may be usefully combined with other therapeutic mechanisms. Data relating to such issues are still being collected. In severe AD, levels of AChE and choline acetyltransferase are decreased by as much as 90% compared with normal, whilst butyrylcholinesterase (BuChE) increases. In such instances, it is possible that BuChE may be a more appropriate therapeutic target. Both AChE and BuChE are aggregated in senile plaques along with beta-amyloid, and investigations are being undertaken to determine whether drugs can be developed that inhibit AChE whilst also acting on beta-amyloid. Deficits in nicotinic binding sites have led to hopes for new nicotinic drugs. Cholinergic therapies can potentially cause unwanted side effects and the search for the 'ideal' inhibitor continues. Combinations of drugs may ultimately prove to be the most productive means of treating patients with AD.
Copyright 2003 John Wiley & Sons, Ltd.
Similar articles
-
Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.Curr Med Res Opin. 2005 Nov;21(11):1809-18. doi: 10.1185/030079905X65655. Curr Med Res Opin. 2005. PMID: 16307702 Clinical Trial.
-
In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.Ann Neurol. 2006 Jan;59(1):13-20. doi: 10.1002/ana.20672. Ann Neurol. 2006. PMID: 16278840
-
[Therapy of Alzheimer disease].Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Neuropsychopharmacol Hung. 2009. PMID: 19731816 Review. Hungarian.
-
Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.Neurochem Int. 2008 Nov;53(5):103-11. doi: 10.1016/j.neuint.2008.06.005. Epub 2008 Jun 17. Neurochem Int. 2008. PMID: 18602955 Review.
-
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.Pharmacogenet Genomics. 2006 Nov;16(11):771-4. doi: 10.1097/01.fpc.0000220573.05714.ac. Pharmacogenet Genomics. 2006. PMID: 17047484 Clinical Trial.
Cited by
-
Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease.J Chromatogr A. 2009 Mar 27;1216(13):2730-8. doi: 10.1016/j.chroma.2008.09.100. Epub 2008 Oct 4. J Chromatogr A. 2009. PMID: 18950780 Free PMC article.
-
Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease.Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:94-9. doi: 10.1016/j.pnpbp.2013.02.002. Epub 2013 Feb 13. Prog Neuropsychopharmacol Biol Psychiatry. 2013. PMID: 23416088 Free PMC article.
-
Multiple 3D-QSAR modeling, e-pharmacophore, molecular docking, and in vitro study to explore novel AChE inhibitors.RSC Adv. 2018 Nov 26;8(69):39477-39495. doi: 10.1039/c8ra08198k. eCollection 2018 Nov 23. RSC Adv. 2018. PMID: 35558010 Free PMC article.
-
Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: critical role of S-adenosyl methionine.J Nutr Health Aging. 2008 Apr;12(4):252-61. doi: 10.1007/BF02982630. J Nutr Health Aging. 2008. PMID: 18373034
-
Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model.RSC Med Chem. 2022 Jun 20;13(8):944-954. doi: 10.1039/d2md00087c. eCollection 2022 Aug 17. RSC Med Chem. 2022. PMID: 36092149 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
